publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
pulmonari
complic
hsct
common
incid
one
third
recipi
section
special
clinic
condit
hematopoiet
stem
cell
transplant
hsct
refer
transplant
stem
cell
bone
marrow
growth
factorstimul
peripher
blood
umbil
blood
treatment
malign
nonmalign
hematolog
autoimmun
genet
diseas
transplant
recipi
risk
seriou
complic
result
pretranspl
cytoreduct
condit
regimen
immunolog
sequela
engraft
allogen
lymphoid
cell
mediat
graftversushost
respons
patient
immunosuppress
statu
infect
secondari
immunosuppress
autopsi
studi
show
pulmonari
complic
respons
death
hsct
recipi
hematopoiet
stem
cell
transplant
classifi
autolog
allogen
syngen
autolog
hsct
patient
receiv
hematopoiet
stem
cell
allogen
hsct
patient
receiv
hematopoiet
stem
cell
nonident
sibl
unrel
match
donor
syngen
hsct
patient
receiv
hematopoiet
stem
cell
genet
ident
twin
sourc
donor
hematopoiet
stem
cell
bone
marrow
peripher
blood
umbil
cord
blood
autolog
syngen
transplant
involv
stem
cell
immunolog
ident
recipi
reaction
graft
host
avoid
allogen
transplant
mismatch
donor
recipi
human
leukocyt
antigen
hla
mediat
graftversushost
diseas
gvhd
may
lead
allograft
reject
factor
determin
type
transplant
perform
includ
natur
stage
underli
diseas
avail
suitabl
donor
medic
condit
recipi
advantag
allogen
transplant
autolog
transplant
includ
higher
likelihood
stem
cell
product
free
tumor
contamin
graftversushost
activ
survey
sever
countri
found
common
indic
hsct
lymphoprolif
disord
leukemia
solid
tumor
nonmalign
disord
lymphoprolif
disord
includ
plasma
cell
disord
hodgkin
diseas
nonhodgkin
lymphoma
autolog
hsct
slightli
common
allogen
hsct
allogen
hsct
frequent
malign
diseas
acut
myeloid
leukemia
common
nonmalign
diseas
bone
marrow
failur
syndrom
autolog
hsct
frequent
indic
plasma
cell
disord
common
nonmalign
indic
includ
bone
marrow
failur
hemoglobinopathi
immun
defici
inherit
diseas
metabol
autoimmun
disord
undergo
hsct
patient
receiv
condit
regimen
goal
reduc
tumor
burden
malign
ablat
bone
marrow
suppress
recipi
immun
system
therebi
allow
engraft
stem
cell
three
regimen
type
myeloabl
condit
reducedintens
condit
nonmyeloabl
condit
classif
base
durat
cytopenia
requir
stem
cell
support
myeloabl
condit
caus
irrevers
cytopenia
stem
cell
support
alway
necessari
wherea
nonmyeloabl
condit
caus
minim
cytopenia
stem
cell
support
may
need
reducedintens
condit
caus
cytopenia
variabl
durat
stem
cell
support
given
convent
myeloabl
condit
regimen
includ
cyclophosphamid
totalbodi
irradi
tbi
busulfan
recent
nonmyeloabl
reducedintens
condit
regimen
use
fludarabin
reduceddos
alkyl
agent
tbi
although
less
intens
regimen
provid
strong
cytoreduct
effect
allow
engraft
donor
stem
cell
subsequ
potenti
benefici
graftversusmalign
effect
nonmyeloabl
reducedintens
condit
regimen
associ
reduc
transplantassoci
morbid
lower
incid
pulmonari
complic
transplant
prophylaxi
allogen
transplant
prevent
gvhd
usual
involv
methotrex
cyclosporin
corticosteroid
vitro
cell
deplet
graft
infus
pulmonari
complic
one
studi
show
elev
pretranspl
level
patient
breast
cancer
undergo
autolog
hsct
associ
increas
posttranspl
risk
pulmonari
toxic
hepat
venoocclus
diseas
recipi
allogen
transplant
infect
complic
recipi
autograft
chronic
immunosuppress
also
gvhd
caus
immunodefici
state
affect
mucos
surfac
reticuloendotheli
system
bone
marrow
factor
predispos
allogen
recipi
fatal
viral
pneumonia
multidrugresist
bacteria
invas
fungi
similarli
bronchiol
obliteran
almost
exclus
seen
allogen
hsct
patient
may
genet
predispos
develop
toxic
hsctrelat
treatment
inde
recent
studi
requir
intens
care
transplant
respiratori
failur
common
caus
critic
ill
pneumonia
lead
infecti
caus
death
hsct
figur
pulmonari
complic
occur
earli
late
posttranspl
cours
infecti
noninfecti
etiolog
present
assort
radiograph
find
pulmonari
complic
hsct
also
vari
depend
indic
type
prepar
regimen
preced
hsct
cellular
interact
graft
host
cell
essenti
elimin
autolog
transplant
obviat
need
immunosuppress
prevent
treat
gvhd
autolog
transplant
associ
lower
incid
infect
particularli
viral
pneumonia
cytomegaloviru
cmv
pneumon
invas
fungal
diseas
opportunist
infect
eg
toxoplasmosi
well
late
airflow
obstruct
defect
relaps
statu
transplant
donorrecipi
hla
mismatch
nonident
risk
factor
pulmonari
complic
mortal
hsct
box
activ
phase
malign
age
year
receipt
hlanonident
donor
marrow
risk
factor
respiratori
failur
hsct
abnorm
pretranspl
pulmonari
function
test
pft
may
predict
subsequ
risk
pulmonari
complic
mortal
reduc
diffus
capac
increas
alveolararteri
oxygen
gradient
independ
risk
factor
interstiti
pneumon
also
independ
associ
increas
earli
mortal
hsct
patient
elev
level
transform
growth
factor
beta
plasma
bronchoalveolar
lavag
bal
fluid
granulocytemacrophag
colonystimul
factor
gmcsf
bal
fluid
seem
increas
risk
overal
risk
pulmonari
infect
patient
receiv
hsct
depend
multipl
risk
factor
includ
chemotherapi
radiationinduc
neutropenia
lung
injuri
induc
condit
regimen
reject
form
gvhd
local
disrupt
host
defens
intens
pathogen
exposur
addit
hsct
recipi
need
develop
function
immun
system
donorderiv
cell
although
product
red
blood
cell
platelet
granulocyt
occur
soon
hsct
product
lymphocyt
especi
cell
consider
delay
first
year
transplant
seriou
infect
occur
otherwis
uncompl
transplant
histocompat
sibl
donor
match
unrel
donor
histocompat
recipi
gvhd
support
care
posttranspl
period
chang
microbiolog
pneumonia
prophylact
administr
trimethoprimsulfamethoxazol
tmpsmx
antivir
antifung
fluoroquinolon
decreas
incid
pneumocysti
jirovecii
cmv
herp
simplex
candida
albican
infect
box
resist
gramneg
gramposit
bacteria
virus
fungi
remain
import
pathogen
bacteri
pneumonia
major
caus
morbid
mortal
patient
receiv
hsct
first
month
transplant
notabl
pneumonia
caus
usual
pathogen
bacteri
pneumonia
frequent
caus
staphylococcu
streptococcu
spp
respect
one
seri
gramneg
organ
includ
pseudomona
klebsiella
escherichia
stenotrophomona
legionella
acinetobact
serratia
proteu
enterobact
citrobact
spp
organ
includ
enterococcu
rare
anaerob
bacteroid
fusobacterium
spp
commun
pathogen
emerg
immedi
posttranspl
period
haemophilu
influenza
common
isol
follow
streptococcu
pneumonia
legionella
spp
fungal
diseas
consid
patient
persist
focal
radiograph
abnorm
respond
empir
antibiot
therapi
nodular
opac
chest
imag
prolong
neutropenia
corticosteroid
use
histori
prior
fungal
infect
suggest
certain
genet
polymorph
appear
play
role
pathogenesi
divers
posthsct
pulmonari
complic
exampl
polymorph
gene
angiotensinconvert
enzym
ace
increas
likelihood
develop
noninfecti
pulmonari
dysfunct
allogen
hsct
polymorph
gene
code
protein
involv
stressinduc
oxid
antioxid
balanc
may
associ
acut
lung
injuri
hsct
patient
genet
polymorph
may
also
basi
increas
suscept
infect
hsct
exampl
polymorph
mannosebind
lectin
gene
donor
recipi
associ
increas
risk
major
infect
although
still
routin
use
clinic
practic
genet
screen
may
lead
refin
predict
risk
pulmonari
complic
futur
patient
undergo
hsct
specif
pulmonari
complic
associ
hsct
tend
occur
rel
welldefin
timelin
time
intens
cytoreduct
therapi
result
pattern
immun
reconstitut
influenc
durat
interv
preengraft
phase
day
transplant
character
prolong
neutropenia
break
mucocutan
barrier
accordingli
infecti
complic
expect
primarili
caus
bacteri
fungal
infect
howev
pulmonari
complic
phase
noninfecti
relat
regimenrel
toxic
earli
postengraft
period
span
day
transplant
character
persist
impair
cellular
humor
immun
part
determin
exogen
immunosuppress
gvhd
defici
immunoglobulin
loss
protect
alveolar
macrophag
period
neutropenia
usual
resolv
decreas
risk
bacteri
fungal
infect
epidemiolog
infecti
etiolog
thu
chang
involv
predominantli
viral
infect
especi
cmv
routin
use
antivir
howev
incid
posttranspl
cmv
pneumonia
decreas
substanti
noninfecti
etiolog
time
includ
engraft
syndrom
delay
pulmonari
toxic
syndrom
late
postengraft
period
begin
day
transplant
time
immun
recoveri
function
variabl
depend
type
hsct
autolog
recipi
recov
rapidli
allogen
recipi
cell
respons
alloantigen
return
normal
immunoglobulin
level
frequent
remain
depress
viral
pathogen
caus
infect
poor
lymphocyt
function
wherea
inadequ
cellular
immun
result
bacteri
fungal
pathogen
noninfecti
etiolog
primarili
respons
pulmonari
complic
seen
time
includ
chronic
gvhd
drugrel
pulmonari
toxic
bronchiol
obliteran
restrict
fibrot
lung
diseas
cryptogen
organ
pneumonia
formerli
boop
present
includ
fever
nonproduct
cough
hypoxia
chest
imag
demonstr
variou
abnorm
frequent
bilater
interstiti
opac
definit
diagnosi
reli
demonstr
viral
inclus
bodi
lung
tissu
difficult
transbronchi
biopsi
specimen
detect
viru
bal
fluid
shell
vial
assay
polymeras
chain
reaction
pcr
viral
cultur
patient
compat
clinic
present
mortal
cmv
pneumonia
posttranspl
patient
exceed
advent
combin
therapi
ganciclovir
intraven
immun
globulin
ivig
improv
surviv
rate
high
use
prophylaxi
reduc
incid
also
delay
onset
diseas
cmv
infect
occur
day
transplant
prophylact
regimen
taken
two
approach
univers
prophylaxi
highrisk
patient
defin
period
engraft
preemptiv
treatment
patient
detect
subclin
viremia
pcr
assay
strategi
reduc
risk
earli
cmv
diseas
accept
practic
guidelin
seroneg
patient
underw
allogen
transplant
seroposit
donor
highest
risk
cmv
pneumonia
infect
pattern
respiratori
virus
hsct
recipi
similar
gener
popul
howev
hsct
recipi
like
develop
lower
respiratori
tract
infect
mortal
respiratori
virus
classic
recogn
caus
diseas
immunocompet
immunocompromis
individu
includ
respiratori
syncyti
viru
rsv
parainfluenza
influenza
new
detect
techniqu
led
increas
identif
respiratori
virus
human
corona
viru
human
metapneumoviru
human
bocaviru
human
rhinoviru
larg
prospect
studi
incid
first
episod
viral
respiratori
infect
recipi
allogen
hsct
recipi
autolog
hsct
commonli
isol
respiratori
virus
influenza
ab
human
rsv
human
metapneumoviru
respiratori
syncyti
viru
usual
caus
upper
respiratori
infect
may
progress
fatal
pneumonia
immunocompromis
patient
late
airflow
obstruct
also
associ
rsv
infect
untreat
rsv
pneumonia
poor
prognosi
mortal
approach
treatment
includ
aerosol
ribavirin
agent
may
ad
although
benefici
effect
concomit
therapi
well
establish
concomit
therapi
includ
ivig
rsvspecif
immunoglobulin
palivizumab
earli
initi
treatment
appear
fundament
success
antivir
therapi
role
preemptiv
therapi
presenc
isol
upper
respiratori
tract
rsv
infect
well
defin
adenoviru
uncommon
caus
pneumonia
isol
patient
hsct
incid
higher
children
affect
upper
lower
respiratori
tract
well
gastrointestin
genitourinari
system
infect
usual
develop
within
first
month
transplant
present
might
includ
pharyng
tracheiti
bronchiti
pneumon
enter
hemorrhag
cystiti
dissemin
diseas
mortal
pulmonari
involv
may
exceed
cidofovir
use
preemptiv
posit
viremia
despit
absenc
symptom
therapeut
treatment
center
success
use
adenovirusspecif
cytotox
cell
treatment
invas
aspergillosi
lead
caus
infecti
death
hsct
patient
mortal
allogen
recipi
despit
treatment
incid
invas
aspergillosi
allogen
recipi
bimod
distribut
case
earli
preengraft
period
character
profound
neutropenia
allogen
autolog
recipi
increas
risk
invas
aspergillosi
allogen
patient
experi
second
period
vulner
howev
postengraft
phase
coincid
develop
chronic
gvhd
need
augment
immunosuppress
vulner
invas
aspergillosi
higher
second
period
neutropenia
case
invas
aspergillosi
limit
lung
sinu
central
nervou
system
involv
also
seen
common
present
symptom
includ
cough
dyspnea
fever
absent
two
third
patient
concomit
pleurit
chest
pain
hemoptysi
clue
radiograph
find
includ
singl
multipl
nodul
caviti
consolid
infiltr
usual
focal
air
crescent
sign
describ
central
nodul
partial
fulli
surround
air
indic
sequestrum
necrot
lung
tissu
separ
surround
parenchyma
halo
sign
comput
tomographi
ct
describ
rim
low
attenu
repres
edema
hemorrhag
surround
pulmonari
nodul
present
patient
neutropenia
invas
pulmonari
aspergillosi
diagnosi
invas
aspergillosi
confirm
demonstr
fungal
element
diseas
tissu
posit
cultur
result
specimen
normal
steril
site
clinic
practic
howev
biopsi
usual
feasibl
thrombocytopenia
coagul
deficit
presumpt
diagnosi
often
substanti
highresolut
ct
hrct
chest
cultur
result
indirect
diagnost
test
detect
galactomannan
antigen
bodi
fluid
random
clinic
trial
compar
voriconazol
amphotericin
b
found
voriconazol
led
better
surviv
improv
respons
initi
therapi
therefor
voriconazol
recommend
primari
treatment
invas
aspergillosi
voriconazol
load
dosag
mgkg
intraven
iv
everi
hour
day
follow
mgkg
iv
everi
hour
although
first
choic
liposom
amphotericin
b
may
use
altern
primari
therapi
posaconazol
mg
everi
hour
firstchoic
agent
prophylaxi
invas
aspergillosi
highrisk
patient
includ
hsct
recipi
gvhd
candida
cryptococcu
zygomycet
includ
mucor
rhizopu
also
import
pathogen
preval
invas
zygomycot
infect
bear
similar
clinic
cours
aspergillu
zygomycet
angioinvas
lead
thrombosi
pulmonari
infarct
hemorrhag
radiograph
show
cavit
halo
sign
mortal
rate
high
despit
treatment
amphotericin
b
surgic
resect
endem
fungi
encount
less
frequent
histoplasma
coccidioid
usual
occur
reactiv
latent
infect
blastomyc
usual
repres
primari
diseas
emerg
fungal
pathogen
report
caus
pulmonari
infect
includ
fusarium
scedosporium
spp
viral
infect
particularli
cmv
pneumonia
import
caus
morbid
mortal
postengraft
period
cytomegaloviru
pneumonia
nonspecif
clinic
insight
obtain
anim
model
stimul
classif
entiti
term
idiopath
pneumonia
syndrom
accord
primari
anatom
site
cellular
damag
interstiti
tissu
vascular
endothelium
airway
epithelium
see
fig
exampl
interstiti
type
injuri
increas
number
cytotox
lymphocyt
cell
express
famili
costimulatori
ligand
alveolar
interstiti
space
vascular
endothelium
type
injuri
injur
endotheli
cell
airway
epithelium
type
injuri
injur
type
ii
alveolar
epitheli
cell
classif
reflect
complex
interact
mechan
pathogen
role
attribut
sever
factor
includ
increas
solubl
inflammatori
mediat
eg
tumor
necrosi
factor
alpha
increas
host
floraderiv
lipopolysaccharid
enhanc
oxid
stress
deplet
pulmonari
surfact
donorderiv
cell
effector
host
antigenpres
cell
donor
accessori
cell
leukocyt
recruit
lung
treatment
hsct
patient
ip
includ
support
care
recent
combin
corticosteroid
use
subcutan
etanercept
associ
high
clinic
respons
rate
recent
seri
immedi
posttranspl
period
pulmonari
toxic
prior
chemoradiotherapi
pretranspl
condit
regimen
may
manifest
fever
dyspnea
cough
hypoxemia
patchi
diffus
mix
interstiti
alveolar
infiltr
chest
radiographi
prospect
studi
document
efficaci
steroid
patient
clinic
practic
prednison
mgkgday
use
treat
lung
toxic
infect
exclud
acut
pulmonari
edema
complic
tend
occur
earli
typic
second
week
hsct
patient
develop
pulmonari
edema
fluid
retent
demonstr
weight
gain
posit
fluid
balanc
first
week
hsct
fluid
retent
correl
left
ventricular
lv
enddiastol
diamet
measur
echocardiographi
find
underlin
import
increas
lv
preload
subsequ
elev
lv
enddiastol
pressur
increas
capillari
hydrostat
pressur
pathophysiolog
pulmonari
edema
hsct
patient
may
also
underli
cardiac
dysfunct
secondari
previou
treatment
chemotherapeut
agent
chest
irradi
noncardiogen
pulmonari
edema
may
result
condit
druginduc
pulmonari
toxic
blood
product
transfus
hepat
venooclus
diseas
diffus
alveolar
damag
histolog
express
acut
lung
injuri
acut
respiratori
distress
syndrom
therefor
end
result
differ
diseas
process
typic
sepsi
drug
toxic
histolog
featur
vari
accord
phase
exud
first
week
organ
exud
phase
histolog
analysi
reveal
intraalveolar
edema
interstiti
widen
hyalin
membran
organ
phase
somewhat
uniform
fibrosi
promin
type
pneumocyt
hyperplasia
diffus
alveolar
hemorrhag
dah
occur
approxim
autolog
allogen
recipi
risk
factor
includ
human
metapneumoviru
rna
paramyxoviru
caus
infect
hsct
recipi
patient
usual
present
upper
respiratori
tract
symptom
may
also
develop
pneumonia
role
antivir
therapi
defin
infect
influenza
type
b
caus
infect
immunocompet
immunocompromis
patient
type
common
influenza
pandem
caus
novel
influenza
viru
reassort
classic
swine
avian
eurasian
swine
north
american
human
infect
novel
character
sever
diseas
patient
specif
risk
factor
includ
immunocompromis
statu
cohort
studi
two
medic
center
found
hsct
recipi
infect
novel
develop
lower
respiratori
infect
case
mortal
zanamivir
oseltamivir
neuraminidas
inhibitor
use
treat
influenza
type
b
amantadin
rimantadin
adamantan
use
influenza
type
viral
infect
includ
herp
simplex
viru
hsv
varicellazost
viru
vzv
human
herpesviru
hhv
type
hsv
common
caus
infect
hsct
recipi
incid
greatli
reduc
acyclovir
prophylaxi
associ
idiopath
pneumonia
syndrom
epsteinbarr
viru
ebv
infect
usual
manifest
posttranspl
lymphoprolif
disord
incid
pneumocysti
jirovecii
pneumonia
formerli
p
carinii
pneumonia
pcp
greatli
reduc
tmpsmx
prophylaxi
prophylaxi
recommend
time
engraft
month
transplant
allogen
recipi
indefinit
augment
immunosuppress
therapi
chronic
gvhd
p
jirovecii
pneumonia
present
approxim
day
transplant
cough
dyspnea
fever
bilater
interstiti
alveolar
infiltr
chest
radiographi
diagnost
yield
bal
almost
despit
tmpsmx
treatment
mortal
high
p
jirovecii
infect
occur
within
first
month
transplant
versu
lateonset
infect
idiopath
pneumonia
syndrom
ip
refer
form
sever
lung
injuri
infecti
etiolog
cardiac
dysfunct
acut
kidney
injuri
iatrogen
fluid
overload
exclud
syndrom
encompass
sever
entiti
vari
clinic
present
heterogen
clinic
manifest
reflect
mani
lung
insult
underli
pathogenesi
ip
includ
toxic
effect
hsct
condit
regimen
immunolog
cellmedi
injuri
inflammatori
cytokin
incid
ip
vari
allogen
hsct
lower
incid
observ
nonmyeloabl
condit
regimen
median
time
onset
ip
day
hsct
rang
day
report
ip
follow
autolog
hsct
predominantli
seen
allogen
hsct
risk
factor
ip
includ
convent
condit
regimen
older
age
diagnosi
acut
leukemia
myelodysplast
syndrom
develop
sever
acut
gvhd
highdos
tbi
time
transplant
mani
patient
remain
asymptomat
pulmonari
function
chang
seen
ild
usual
secondari
treatment
condit
regimen
particularli
contain
carmustin
bronchiol
obliteran
oblit
bronchiol
complic
follow
allogen
hsct
rare
may
also
occur
autolog
hsct
incid
bronchiol
obliteran
differ
report
rang
risk
factor
oblit
bronchiol
includ
chronic
gvhd
older
age
presenc
obstruct
disturb
hsct
viral
infect
respiratori
tract
busulfanbas
condit
regimen
close
associ
gvhd
led
expert
claim
bronchiol
obliteran
may
inde
repres
lung
manifest
gvhd
activ
donorderiv
lymphocyt
play
import
role
pathogenesi
bronchiol
obliteran
cell
target
recipi
epitheli
cell
bronchiol
lead
inflammatori
reaction
tolllik
signal
donorderiv
hematopoiet
cell
also
appear
import
factor
caus
alloimmun
oblit
bronchiol
tend
occur
late
typic
day
hsct
common
symptom
dri
cough
dyspnea
wheez
physic
examin
may
reveal
decreas
breath
sound
wheez
inspiratori
squeak
furthermor
physic
examin
often
reveal
sign
gvhd
outsid
lung
skin
manifest
minor
patient
respiratori
manifest
diagnosi
establish
pft
chest
radiograph
usual
normal
although
patient
advanc
diseas
may
sign
hyperinfl
bronchiectasi
area
scar
hrct
scan
sensit
previous
mention
abnorm
valuabl
show
air
trap
mosaic
attenu
expir
pft
show
obstruct
pattern
fev
fvc
ratio
less
decreas
fev
greater
pretranspl
valu
treatment
hsct
patient
bronchiol
obliteran
involv
corticosteroid
prednison
mgkg
daili
intensif
immunosuppress
therapi
pulmonari
venoocclus
diseas
pvod
character
oblit
fibrot
vasculopathi
affect
mainli
small
branch
pulmonari
venou
circul
pvod
may
idiopath
secondari
anoth
diseas
diseas
risk
factor
associ
develop
pvod
includ
exposur
chemotherapeut
agent
eg
carmustin
mitomycin
c
bleomycin
autolog
allogen
hsct
solidorgan
transplant
radiotherapi
autoimmun
diseas
patient
seen
sever
month
transplant
progress
dyspnea
exert
fatigu
may
also
pleural
effus
right
upper
quadrant
tender
ascit
chest
radiographi
reveal
interstiti
edema
abnorm
hrct
scan
includ
groundglass
opac
centrolobular
distribut
septal
thicken
mediastin
lymphadenopathi
diagnosi
pvod
definit
establish
histolog
analysi
lung
biopsi
specimen
lung
biopsi
indic
high
mortal
risk
histolog
analysi
reveal
fibrosi
venul
small
vein
interlobular
septa
pulmonari
circul
result
intralumin
thrombosi
pulmonari
arteri
may
display
medial
hypertrophi
eccentr
intim
fibrosi
rightsid
cardiac
highdos
chemotherapi
receiv
transplant
irradi
advanc
age
rapid
immun
system
reconstitut
also
theoriz
contribut
dah
neutrophil
influx
lung
may
accentu
injuri
precipit
hemorrhag
typic
symptom
dyspnea
hemoptysi
cough
fever
may
also
present
although
highli
suggest
dah
appropri
clinic
set
hemoptysi
alway
present
patient
usual
seen
periengraft
period
within
first
month
transplant
patient
dah
seen
late
day
diagnost
criteria
propos
diagnos
dah
includ
alveolar
injuri
evid
diffus
lung
infiltr
increas
alveolararteri
oxygen
gradient
absenc
pulmonari
infect
bal
fluid
increasingli
bloodier
return
three
separ
subseg
hemosiderinladen
macrophag
higher
radiograph
find
dah
often
nonspecif
includ
interstiti
alveolar
pattern
usual
bilater
distribut
spare
peripher
lung
area
mainstay
treatment
hsct
patient
dah
system
steroid
therapi
institut
promptli
report
regimen
methylprednisolon
mg
everi
hour
day
follow
slow
taper
week
engraft
syndrom
clinic
entiti
occur
often
autolog
hsct
also
follow
allogen
hsct
characterist
featur
develop
syndrom
within
hour
engraft
etiolog
unclear
may
attribut
increas
cytokin
releas
neutrophil
degranul
engraft
main
clinic
manifest
engraft
syndrom
includ
fever
erythroderm
rash
noncardiogen
pulmonari
edema
patient
may
also
present
hepat
dysfunct
renal
insuffici
weight
gain
transient
encephalopathi
treatment
includ
support
care
steroid
mild
case
steroid
may
warrant
delay
pulmonari
toxic
syndrom
refer
pulmonari
toxic
caus
chemotherapi
occur
patient
undergo
autolog
hsct
syndrom
associ
regimen
contain
carmustin
cyclophosphamid
often
present
week
month
hsct
distinct
featur
allow
differenti
idiopath
pneumonia
syndrom
exampl
delay
pulmonari
toxic
syndrom
character
high
incid
low
mortal
signific
steroid
respons
symptom
includ
dyspnea
nonproduct
cough
occasion
fever
radiograph
abnorm
nonspecif
alway
correl
symptom
worsen
pulmonari
function
common
abnorm
ct
scan
includ
groundglass
opac
mix
linearnodular
opac
pft
show
decreas
diffus
capac
dlco
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
total
lung
capac
tlc
may
also
decreas
usual
lesser
extent
lung
biopsi
show
alveolar
septal
thicken
interstiti
fibrosi
type
pneumocyt
hyperplasia
consist
drug
toxic
treatment
consist
steroid
interstiti
pneumon
interstiti
lung
diseas
ild
manifest
diminish
dlco
tlc
occur
virtual
term
pulmonari
cytolyt
thrombi
describ
vasculopathi
occur
pediatr
allogen
hsct
recipi
character
oblit
arteriopathi
occlus
vascular
lesion
hemorrhag
infarct
entiti
resolv
spontan
without
specif
therapi
pulmonari
alveolar
proteinosi
also
report
revers
caus
respiratori
failur
allogen
hsct
acut
leukemia
diagnost
evalu
hsct
patient
inform
obtain
durat
pulmonari
complic
radiograph
abnorm
individu
patient
factor
exposur
toxic
drug
histori
receiv
chest
radiotherapi
current
previou
immunosuppress
regimen
infect
prophylaxi
cmv
statu
donor
recipi
histori
previou
opportunist
invas
fungal
diseas
use
inform
may
obtain
pft
sputum
examin
chest
imag
serolog
studi
initi
imag
evalu
involv
chest
radiograph
normal
symptomat
patient
proven
infiltr
lung
diseas
sensit
chest
ct
differ
pattern
may
suggest
specif
diseas
process
exampl
nodular
infiltr
typic
fungal
infect
nocardia
cryptococcu
also
may
present
nodular
mass
focal
infiltr
usual
reflect
infecti
process
noninfecti
process
present
focal
infiltr
includ
pulmonari
emboli
acut
radiat
pneumon
carcinoma
diffus
infiltr
nonspecif
often
repres
pulmonari
edema
preengraft
phase
infect
engraft
pleural
effus
suggest
bacteri
mycobacteri
nocardi
infect
well
noninfecti
condit
pulmonari
edema
hepat
venoocclus
diseas
pulmonari
infarct
malign
pulmonari
function
test
obtain
hsct
transplant
symptomat
patient
regularli
schedul
interv
highrisk
individu
pretranspl
abnorm
dlco
alveolararteri
oxygen
differ
independ
risk
factor
interstiti
pneumon
death
transplant
typic
pft
abnorm
includ
declin
lung
volum
deceas
dlco
worsen
airflow
limit
presenc
galactomannan
cell
wall
compon
releas
aspergillu
spp
serum
indic
invas
aspergillosi
detect
enzymelink
immunosorb
assay
use
cutoff
optic
densiti
test
sensit
specif
posit
predict
valu
neg
predict
valu
galactomannan
assay
diagnosi
invas
aspergillosi
also
evalu
bal
fluid
use
cutoff
optic
densiti
test
show
sensit
specif
elev
level
serum
typic
associ
invas
aspergillosi
invas
candidiasi
specif
particular
fungal
infect
catheter
typic
reveal
precapillari
pattern
pulmonari
hypertens
increas
mean
pulmonari
arteri
pressur
normalrang
pulmonari
capillari
wedg
pressur
pulmonari
vasodil
exacerb
pulmonari
edema
anecdot
report
describ
pvod
patient
respons
highdos
corticosteroid
posttranspl
lymphoprolif
disord
term
use
differ
b
cell
hyperprolif
state
may
benign
malign
behavior
may
follow
solidorgan
transplant
allogen
hsct
lymphoid
prolifer
character
cell
dysfunct
result
condit
regimen
presenc
epsteinbarr
viru
cell
dysfunct
lead
prolifer
ebvinfect
b
lymphocyt
incid
vari
risk
factor
disord
includ
hlamismatch
donor
cell
deplet
graft
antit
cell
agent
older
age
donor
splenectomi
mismatch
cmv
ebv
statu
recipi
donor
time
transplant
develop
posttranspl
lymphoprolif
disord
day
patient
usual
seen
within
first
month
transplant
lymph
node
liver
spleen
involv
often
relaps
origin
malign
especi
lymphoma
secondari
lymphoma
lung
involv
seen
patient
treatment
consist
reduct
immunosuppress
therapi
prophylact
administr
rituximab
hsct
propos
prevent
posttranspl
lymphoprolif
disord
highrisk
patient
cryptogen
organ
pneumonia
cop
formerli
bronchiol
obliteran
organ
pneumonia
boop
inflammatori
condit
follow
allogen
autolog
hsct
onset
cop
vari
usual
occur
day
hsct
residu
treat
cmv
pneumon
relat
chronic
gvhd
idiopath
patient
present
dri
cough
dyspnea
fever
physic
examin
may
reveal
crackl
inspiratori
squeak
chest
hrct
find
includ
patchi
consolid
groundglass
attenu
randomli
distribut
nodul
treatment
includ
steroid
therapi
oral
prednison
initi
dose
mgkg
daili
taper
month
recipi
hsct
overal
rate
intens
care
unit
admiss
common
caus
icu
admiss
respiratori
failur
follow
shock
secondari
sepsi
independ
risk
factor
requir
assist
mechan
ventil
includ
older
age
activ
malign
transplant
donorrecipi
hla
mismatch
review
demonstr
pool
mortal
hsct
recipi
requir
invas
mechan
ventil
noninvas
positivepressur
ventil
select
patient
revers
acut
respiratori
failur
use
observ
studi
show
surviv
benefit
hsct
recipi
patient
cancer
critic
ill
hsct
recipi
also
import
compli
current
evidencebas
precept
critic
care
medicin
exampl
patient
acut
respiratori
syndrom
undergo
mechan
ventil
tidal
volum
mlkg
ideal
bodi
weight
target
newer
diagnost
techniqu
allow
accur
diagnosi
usual
viral
respiratori
infect
also
detect
emerg
virus
previous
undetect
nasopharyng
swab
assay
employ
multiplex
pcr
detect
differ
respiratori
viru
type
subtyp
singl
rapid
test
determin
cmv
serolog
statu
recipi
donor
essenti
pretranspl
screen
serolog
statu
recipi
oppos
donor
primari
determin
cmv
convers
shell
vial
cultur
monoclon
antibodi
requir
hour
test
antigenemia
rapid
standard
semiquantit
inexpens
nucleic
acid
amplif
pcr
dna
extract
infect
leukocyt
also
allow
rapid
diagnosi
detect
infect
week
viral
cultur
becom
posit
week
posit
antigenemia
highli
sensit
bronchoscopi
bal
potenti
identifi
caus
acut
respiratori
failur
hsct
patient
howev
also
carri
risk
especi
hypoxem
patient
role
bronchoscopi
prospect
evalu
multicent
observ
studi
cancer
patient
hsct
recipi
acut
respiratori
failur
receiv
bronchoscopi
bal
well
noninvas
diagnost
test
noninvas
test
diagnost
yield
bal
bronchoscopi
although
investig
provid
diagnosi
one
third
patient
bronchoscopi
bal
associ
respiratori
deterior
half
nonintub
patient
thu
although
routin
use
bronchoscopi
hsct
recipi
acut
respiratori
failur
remain
controversi
select
patient
bronchoscopi
may
provid
mean
accur
determin
etiolog
lung
diseas
transthorac
needl
aspir
ct
fluoroscop
guidanc
high
sensit
detect
pulmonari
complic
hsct
patient
common
find
infect
malign
howev
pneumothorax
also
common
complic
may
requir
chest
tube
placement
diagnosi
made
either
bronchoscopi
transthorac
needl
aspir
surgic
lung
biopsi
either
open
thoracotomi
videoassist
thoracoscop
approach
may
consid
next
although
surgic
lung
biopsi
sensit
procedur
may
associ
wors
outcom
thu
recommend
primarili
hematopoiet
stem
cell
transplant
recipi
whose
test
result
like
significantli
alter
manag
